Still’s disease
Conditions
Brief summary
Clinical response defined by achieving a composite endpoint
Detailed description
Adverse events and serious adverse events. Safety measures including vital signs, ECG and laboratory assessments throughout the study, Clinical response defined by achieving a composite endpoint, Change in physician´s assessment. Change in laboratory features of Macrophage Activation Syndrome, Glucocorticoid dose compared to baseline, Change from baseline in patient/parent assessment of physical function, Clinically inactive disease whilst on non‑treatment dose corticosteroid at any time during the study
Interventions
DRUGMAS825
DRUG-
Sponsors
Novartis Pharma AG
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response defined by achieving a composite endpoint | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events and serious adverse events. Safety measures including vital signs, ECG and laboratory assessments throughout the study, Clinical response defined by achieving a composite endpoint, Change in physician´s assessment. Change in laboratory features of Macrophage Activation Syndrome, Glucocorticoid dose compared to baseline, Change from baseline in patient/parent assessment of physical function, Clinically inactive disease whilst on non‑treatment dose corticosteroid at any time during the study | — |
Countries
France, Germany, Italy, Netherlands, Spain
Outcome results
None listed